The Star of TomorrowCAR-T分析课件.pptVIP

Department of Hematology, General Hospital of Shenyang Military Region 2014.12.03 The Star of Tomorrow:CAR-T Background 1 The Research Progress of CAR-T 2 Efficacy、Persistence and Toxicity of CAR-T 3 The Furture of CAR-T 4 Contents ■T cells can be genetically modified to express chimeric antigen receptors (CARs), which are fusion proteins made up of antigen-recognition moieties and T?cell activation domains ■CD19 is a suitable target for CAR T cells because it is expressed by B?cell malignancies, but not by normal essential tissues ■ Depleting endogenous lymphocytes by administering chemotherapy or radiotherapy before infusions of adoptively transferred T cells enhances the in vivo activity of the T cells ■ Patients have achieved complete remissions during clinical trials of anti-CD19 CAR T cells; however, acute toxicities associated with elevated serum levels of inflammatory cytokines were noted in trials ■ Evidence for biological activity is provided by long-term depletion of CD19+ normal B cells from several patients receiving infusions of anti-CD19 CAR T cells ■ Adoptive transfer of anti-CD19 CAR T cells is a potent new form of immunotherapy that has the potential to become an important therapy option for some advanced-stage B?cell malignancies Background NATURE REVIEWS | CLINICAL ONCOLOGY Chimeric antigen receptors day 0 after 2days resuspended with low IL-2 concentration loaded with anti-CD19 CAR viral vector expanded for 9 more days the beads were removed A schematic of our current approach to anti-CD19 CAR T cell therapy is shown NATURE REVIEWS | CLINICAL ONCOLOGY The Research Progress of CAR-T ■In the last 5 years, chimeric antigen receptor (CAR)-redirected T cells have emerged from the bench and made splashy headlines in the clinical setting at a number of academic institutions. It is not surprising that CAR T cells directed to hematologic malignancies have been the first ones tested, given the extent of the known surface antigens expressed on hematolo